|
 Bangalore-based Biocon jointly developed biosimilar
trastuzumab, which received the Indian drug regulator's marketing
approval in November, with U.S.-based Mylan Inc.
About 150,000 people are diagnosed with breast cancer every year in
India, of which 25 percent are eligible for treatment with
trastuzumab, Biocon said.
Roche decided not to pursue a patent application for its breast
cancer drug Herceptin in India, paving the way for generic
drugmakers to produce cheaper copies, known as biosimilars because
they are not identical to the original drug.
Global sales for Herceptin were valued at about $6.4 billion in
2012, including about $21 million in India, Biocon said.
(Reporting by Aradhana Aravindan;
editing by Sonya Hepinstall)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
